Literature DB >> 17172827

The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage.

Emma Bell1, Rakesh Premkumar, Jane Carr, Xiaohong Lu, Penny E Lovat, Ursula R Kees, John Lunec, Deborah A Tweddle.   

Abstract

We previously reported that 3 p53 wild type (wt) MYCN amplified (MNA) neuroblastoma cell lines failed to G1 arrest after DNA damage despite induction of p53, p21(WAF1) and MDM2. We hypothesised that this was due to high MYCN expression. p53 responses to DNA damage were examined in an additional 13 p53 wt neuroblastoma cell lines. MNA was significantly associated with a failure to G1 arrest after DNA damage (p < 0.001) and higher levels of apoptosis after irradiation (p < 0.05). p21(WAF1) and hypophosphorylated (hypo) RB accumulation post irradiation were significantly lower in cell lines that failed to G1 arrest (p < 0.05). Conditional MYCN expression in non-MNA SHEP Tet21N cells did not affect the G1 arrest after irradiation. MYCN knockdown using siRNA in 3 p53 wt MNA cell lines did not restore a G1 arrest after irradiation, but increased the baseline G1 population, p21(WAF1) and hypo RB expression. MYCN siRNA also caused a G1 arrest in a p53 mutant MNA cell line. This study is the first to determine that MNA correlates with a failure to G1 arrest and attenuated p21(WAF1) induction; however MYCN expression alone is not causally responsible.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172827     DOI: 10.4161/cc.5.22.3443

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  24 in total

1.  COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib.

Authors:  Emma Bell; Frida Ponthan; Claire Whitworth; Deborah A Tweddle; John Lunec; Christopher P F Redfern
Journal:  Clin Exp Metastasis       Date:  2014-05-25       Impact factor: 5.150

2.  p53 is a direct transcriptional target of MYCN in neuroblastoma.

Authors:  Lindi Chen; Nunzio Iraci; Samuele Gherardi; Laura D Gamble; Katrina M Wood; Giovanni Perini; John Lunec; Deborah A Tweddle
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

3.  A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene.

Authors:  Kristina A Cole; Edward F Attiyeh; Yael P Mosse; Michael J Laquaglia; Sharon J Diskin; Garrett M Brodeur; John M Maris
Journal:  Mol Cancer Res       Date:  2008-05       Impact factor: 5.852

4.  CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.

Authors:  Sina Gogolin; Volker Ehemann; Gabriele Becker; Lena M Brueckner; Daniel Dreidax; Steffen Bannert; Ingo Nolte; Larissa Savelyeva; Emma Bell; Frank Westermann
Journal:  Cell Cycle       Date:  2013-03-05       Impact factor: 4.534

5.  Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma.

Authors:  Jørn R Henriksen; Bjørn Helge Haug; Jochen Buechner; Ellen Tømte; Cecilie Løkke; Trond Flaegstad; Christer Einvik
Journal:  BMC Dev Biol       Date:  2011-01-03       Impact factor: 1.978

6.  MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.

Authors:  L D Gamble; U R Kees; D A Tweddle; J Lunec
Journal:  Oncogene       Date:  2011-07-04       Impact factor: 9.867

7.  Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.

Authors:  Daisy Corvetta; Olesya Chayka; Samuele Gherardi; Cosimo W D'Acunto; Sandra Cantilena; Emanuele Valli; Izabela Piotrowska; Giovanni Perini; Arturo Sala
Journal:  J Biol Chem       Date:  2013-01-28       Impact factor: 5.157

8.  p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance.

Authors:  Lindi Chen; Deborah A Tweddle
Journal:  Front Oncol       Date:  2012-11-28       Impact factor: 6.244

9.  MYCN transgenic zebrafish model with the characterization of acute myeloid leukemia and altered hematopoiesis.

Authors:  Li-Jing Shen; Fang-Yuan Chen; Yong Zhang; Lan-Fang Cao; Ying Kuang; Min Zhong; Ting Wang; Hua Zhong
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

10.  Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.

Authors:  Veronica Veschi; Marialaura Petroni; Beatrice Cardinali; Carlo Dominici; Isabella Screpanti; Luigi Frati; Armando Bartolazzi; Alberto Gulino; Giuseppe Giannini
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.